Search

Search Constraints

You searched for: Author/Creator Szer, Jeffrey

Search Results

1. Assessment of human antihuman antibodies to eculizumab after long‐term treatment in patients with paroxysmal nocturnal hemoglobinuria. Issue 3 (22nd February 2016)

2. Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. Issue 7 (2nd July 2016)

3. Enzyme replacement therapy with taliglucerase alfa: 36‐month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase. Issue 7 (18th May 2016)

4. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Issue 3 (March 2018)

5. Long‐term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non‐Hodgkin lymphoma. (17th April 2017)

6. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. (25th April 2013)

7. Managing haematology and oncology patients during the COVID‐19 pandemic: interim consensus guidance. Issue 10 (13th May 2020)

8. Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation. Issue 1 (2nd January 2017)

9. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low/intermediate‐1–risk myelodysplastic syndrome and thrombocytopenia. Issue 12 (4th April 2014)

10. Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low/intermediate‐1–risk myelodysplastic syndrome and thrombocytopenia. Issue 12 (4th April 2014)